Target intelligence / Profile preview

Solute carrier family 37 member 2 (SLC37A2)

Target
SLC37A2
Molecular classification
Transporter, Sugar-phosphate:phosphate exchanger, Solute carrier family protein
01

Overview

Solute carrier family 37 member 2 (SLC37A2) is an endoplasmic reticulum-associated transporter that functions as a phosphate-linked glucose-6-phosphate (G6P) antiporter, catalyzing the exchange of G6P and inorganic phosphate across membranes[1][2][4][5]. SLC37A2 differs from SLC37A4 (the canonical G6P transporter in gluconeogenic tissues) in that it does not couple to glucose-6-phosphatase and its function is not inhibited by chlorogenic acid[1][2][4]. SLC37A2 is highly expressed in macrophages, spleen, and thymus, with expression markedly upregulated during macrophage differentiation[4]. In bone, SLC37A2 is essential for normal osteoclast function, localizing to lysosome-related organelles involved in bone resorption; knockout in mice results in increased bone mass due to impaired osteoclast activity[3]. Its precise physiological substrate remains incompletely defined, and its role in human disease is under investigation, but it has emerged as a potential therapeutic target for metabolic bone disorders[3][4].

Other names
Glucose-6-phosphate exchanger SLC37A2SLC37A2FLJ00171SPX2Sugar-phosphate exchange protein 2pp11662Solute carrier family 37 (glucose-6-phosphate transporter) member 2Solute carrier family 37 (glycerol-3-phosphate transporter) member 2Sugar phosphate exchanger 2
02

Mechanism of action

Not established for drugs (no approved inhibitors or modulators).

03

Biological functions

Glucose-6-phosphate transportSugar-phosphate exchangeMacrophage biology (expression induced in macrophages, regulates immune cell metabolism)Bone metabolism regulation (in osteoclasts)
04

Disease associations

Metabolic bone disease (e.g., high bone mass via osteoclast dysfunction)Potential role in immune response/metabolism (macrophage and neutrophil function)
05

Safety considerations

No reported therapeutic targeting in humans to date; functional studies in mice suggest modulation may affect bone density and immune cell function
06

Interacting drugs

None directly established as of current knowledge. No drugs are reported to directly target SLC37A2 in humans.
07

Biomarkers

Likely increased expression during macrophage differentiation (potential immune marker)

Beyond the preview

Go deeper on Solute carrier family 37 member 2 (SLC37A2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 37 member 2 (SLC37A2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call